Analytical Data
-
Gene name
TSK
- Application
-
Alternative Names
E2IG4; TSKU; LRRC54; Tsukushi; E2-induced gene 4 protein; Leucine Rich Repeat Containing 54; Tsukushi Small Leucine Rich Proteoglycan Homolog
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8CBR6
-
Expression Region
Glu30~Gln307
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TSK (thymidine kinase 1) is a crucial enzyme involved in the nucleotide salvage pathway, playing a significant role in DNA synthesis and repair. Its function is particularly important in rapidly proliferating cells, such as those found in tumors, making TSK a potential target for cancer therapy. Research into TSK has garnered attention due to its association with various cancers and its potential as a biomarker for tumor progression and patient prognosis. Moreover, recombinant TSK proteins have been developed for use in diagnostic assays and therapeutic applications, including targeted drug delivery systems. Understanding the structural and functional properties of TSK can aid in the design of inhibitors that specifically target cancer cells while sparing normal tissues. Current studies are focused on elucidating the enzyme's kinetic properties, substrate specificity, and the molecular mechanisms of its regulation within the cellular context. This research not only aims to improve cancer treatment strategies but also enhances our understanding of cellular metabolism and the interplay between enzyme activity and disease states.
